Newsroom
Sorted by: Latest
-
Combined Shareholders’ Meeting of SEB S.A., May 12, 2026
ECULLY, France--(BUSINESS WIRE)--Regulatory News: The Combined Shareholders Meeting of SEB S.A. (Paris:SK) took place on May 12, 2026, and was chaired by Thierry de La Tour d'Artaise, Chairman of the Board of Directors, at Pavillon Gabriel in Paris. Shareholders representing 71.32% of voting rights in the Ordinary Annual General Meeting (OAGM) and 71.32% of voting rights in the Extraordinary Annual General Meeting (EAGM), i.e., 4,068 shareholders present or represented by proxy in OAGM and 4,06...
-
Phillips 66 announces Zeus Gas Plant and a third Coastal Bend Fractionator, advancing integrated wellhead-to-market strategy in the Permian and on the Gulf Coast
HOUSTON--(BUSINESS WIRE)--Phillips 66 today announced it is moving forward with the Zeus Gas Plant and a third Coastal Bend Fractionator....
-
Booz Allen and Anduril Partner to Deploy C2, Cyber, and Zero Trust Capabilities on Menace and Lattice
MCLEAN, Va. & COSTA MESA, Calif.--(BUSINESS WIRE)--Anduril and Booz Allen are partnering to enable unified mission software, cyber & RF effects, and secure communications on a single system at the edge...
-
Visa and Jason Sudeikis Turn the Simplest Goal in Football Into the Biggest Fan Moments at the FIFA World Cup 2026™
SAN FRANCISCO--(BUSINESS WIRE)--At the FIFA World Cup 2026™, everything can change in a split second. A quick pass. A simple finish. A tap in goal. This summer, Visa (NYSE: V), the Worldwide Payment Technology Partner of the FIFA World Cup 2026™, is turning those fleeting moments into something much bigger—launching Tap In, a bold new global campaign based on the belief that everything is a tap in with Visa. Built around one of football’s most recognizable finishes, Tap In takes the simplest to...
-
Infowerk Materials: Erweitertes Produktportfolio deutlich unter europäischen Marktpreisen
RADEBEUL, Deutschland--(BUSINESS WIRE)--Infowerk Materials erweitert sein Produktportfolio um neue Papierqualitäten sowie LFP-Materialien und bleibt deutlich unter europäischen Marktpreisen....
-
Ford Energy and EDF power solutions North America Announce Five-Year Framework Agreement for Up to 20 GWh of Battery Energy Storage Systems
DEARBORN, Mich. & SAN DIEGO--(BUSINESS WIRE)--Ford Energy, a wholly owned subsidiary of Ford Motor Company, and EDF power solutions North America, an entity of the EDF Group, today announced the signing of a five-year framework agreement under which EDF power solutions will have the ability to procure up to 4 gigawatt hours (GWh) of DC Block battery energy storage systems (BESS) annually, representing a total potential volume of up to 20 GWh over the term of the agreement. The framework agreeme...
-
Target RWE and NoviSci Rebrand as Pedestal Health and Headwater Science
DURHAM, N.C.--(BUSINESS WIRE)--Target RWE and NoviSci, two leaders in evidence generation, today announced they will rebrand as Pedestal Health and Headwater Science. These two distinct companies will work to build a modern evidence-generation engine for life sciences organizations, navigating the most complex and consequential research challenges. Pedestal Health (formerly Target RWE) is a full-service evidence generation partner for life sciences organizations. The company delivers scientific...
-
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled. There are 1.4 billion people worldwide living with hypertension.1 In the US, approximately 50% of patients living with hypertension who are already taking multiple antihypertensive me...
-
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a...
-
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parabilis Medicines today announced a strategic research collaboration with Regeneron Pharmaceuticals, Inc. to discover and develop multiple therapeutic candidates based on Parabilis’s Helicon™ peptide platform, with a particular focus on Antibody-Helicon™ Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” targets. Helicons are stabilized, cell-penetrant alpha-helical peptides designed to engage intra...